Search Results

You are looking at 81 - 90 of 486 items for :

  • "locally advanced" x
  • Refine by Access: All x
Clear All
Full access

Michael Xiang, A. Dimitrios Colevas, F. Christopher Holsinger, Quynh-Thu X. Le, and Beth M. Beadle

. Bourhis J , Sire C , Graff P , . Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial

Full access

S. Machele Donat

the surveillance, epidemiology and end results program data base . J Urol 2003 ; 169 : 946 – 950 . 24 Grossman HB Natale RB Tangen CM . Neoadjuvant chemotherapy plus cytstectomy compared with cystectomy alone for locally advanced bladder

Full access

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass

trials. 125 In addition, a recent Cochrane review of 6 randomized controlled trials found that chemotherapy added to preoperative RT in patients with locally advanced stage III rectal cancer reduced the risk of local recurrence, but had no effect on OS

Full access

Lisa Hazard, Gary Yang, Mary Frances McAleer, James Hayman, and Christopher Willett

whole body FDG18 PET imaging to predict pathologic response to induction chemoradiotherapy in locally advanced esophageal cancer: a prospective phase II trial . Int J Radiat Oncol Biol Phys 2003 ; 57 : S165 – 166 . 7. Fukunaga T Okazumi S

Full access

Jaffer A. Ajani

gastroesophageal junction . N Engl J Med 2001 ; 345 : 725 – 730 . 5. Cooper JS Guo MD Herskovic A . Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01) . Radiation Therapy

Full access

Petros Grivas, Meaghan Roach, Vivek Pawar, Caroline Huber, Suepattra May-Slatter, Isha Desai, Jane Chang, and Murtuza Bharmal

Background: The treatment landscape for inoperable locally advanced and/or mUC has evolved with the availability of 1L immune checkpoint inhibitors (ICIs), including approval of avelumab maintenance. However, the real world decision-making process

Full access

Margaret A. Tempero, J. Pablo Arnoletti, Stephen Behrman, Edgar Ben-Josef, Al B. Benson III, Jordan D. Berlin, John L. Cameron, Ephraim S. Casper, Steven J. Cohen, Michelle Duff, Joshua D.I. Ellenhorn, William G. Hawkins, John P. Hoffman, Boris W. Kuvshinoff II, Mokenge P. Malafa, Peter Muscarella II, Eric K. Nakakura, Aaron R. Sasson, Sarah P. Thayer, Douglas S. Tyler, Robert S. Warren, Samuel Whiting, Christopher Willett, and Robert A. Wolff

neoadjuvant therapy (see pages 977, 978, and 979), and for patients staged with locally advanced and unresectable pancreatic cancer or metastatic disease (see page 981). A histologic diagnosis of adenocarcinoma of the pancreas is often made using fine

Full access

Nikki Tang and Desiree Ratner

the implementation of Hedgehog (Hh) pathway inhibitors in daily practice as neoadjuvant therapy of locally advanced BCCs with aggressive, recurrent, or metastatic features, and presents a case illustrating the authors' experience. Although results from

Full access

Pooja Ghatalia and Elizabeth R. Plimack

-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy. Two of these agents, atezolizumab and pembrolizumab, are also approved for frontline treatment of selected cisplatin-ineligible patients with locally advanced or

Full access

Holly Dushkin and Massimo Cristofanilli

, together with accumulating molecular and epidemiologic data, also supports the concept that IBC may be a distinct biologic entity rather than a subtype on the spectrum of locally advanced breast cancer. In fact, several important epidemiologic aspects of